In vitro growth of functional islets of Langerhans and in vivo uses thereof

• US 6,001,647 A
• Filed: 10/25/1995
• Issued: 12/14/1999
• Est. Priority Date: 04/28/1994
• Status: Expired due to Fees

• Current Assignee: University of Florida Research Foundation, Incorporated (State University System of Florida)
• Original Assignee: Ixion Biotechnology Inc. (Galderma Holding SA)
• Inventors: Cornelius, Janet G., Peck, Ammon B.
• Primary Examiner(s): Lankford, Jr., Leon B.
• Application Number:
  US08/547,746
• Time in Patent Office: 1,511 Days
• Field of Search: 435/325, 435/383, 435/384, 435/392
• US Class Current: 435/325
• CPC Class Codes: A01K 2217/05 Animals comprising random inserted nucleic acids (transgenic)
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C07K 14/62 Insulins
• CPC Class Codes: C12N 2500/34 Sugars
• CPC Class Codes: C12N 5/0678 Stem cells; Progenitor cells; Precursor cells

Abstract

The subject invention concerns new methods which make it possible, for the first time, to grow functional islets in in vitro cultures. The subject invention also concerns the use of the in vitro grown islet-like structures for implantation into a mammal for in vivo therapy of diabetes. The subject invention further concerns a process using the in vitro grown islet implants for growing an organ in vivo that has the same functional, morphological and histological characteristics as those observed in normal pancreatic tissue. The ability to grow these cells in vitro and organs in vivo opens up important new avenues for research and therapy relating to diabetes.

Claims

1. A method for the in vitro growth of islet producing stem cells, IPSCs, to produce islet cells or an islet-like structure which comprises culturing pancreatic cells from a mammalian species in a basal nutrient medium supplemented with normal serum at below about 0.5% and glucose at below about 1 mM, allowing said IPSCs to grow for at least about 3 weeks, and initiating cellular differentiation into mature islet cells by re-feeding the IPSCs in culture with a nutrient medium supplemented with normal serum at about 0.5-10% and glucose at about 2.5 mM-10 mM.

2. The method, according to claim 1, wherein the pancreatic cells are human islet cells and the serum is normal human serum.

3. The method, according to claim 1, wherein the pancreatic cells are mouse islet cells and the serum is normal mouse serum.

4. A method, according to claim 1, wherein said nutrient medium comprises a high amino acid nutrient medium.

5. The method, according to claim 1, wherein the culture medium used to re-feed said cell culture further comprises glucose.

6. The method of claim 5 wherein differentiation is enhanced by inclusion of about 10-25 mM glucose, hepatocyte growth/scatter factor, keratinocyte growth factor, fibroblast growth factor, epidermal growth factor, insulin-like growth factor, nicotinamide, or autocrine growth factors produced by IPSCs.

7. The method of claim 6 in which the glucose concentration in the re-fed medium is about 16.7 mM.

8. The method, according to claim 1, wherein differentiation of cultured stem cells is initiated at about 4 to 5 weeks of culture growth by re-feeding of said pancreatic cell culture with the nutrient medium supplemented with homologous normal serum.

9. The method, according to claim 1, wherein after cell differentiation is initiated by re-feeding the culture, the culture is re-fed at about one-week intervals.

10. The method, according to claim 1, wherein the normal serum is obtained from the same mammalian species from which the islet cells were obtained.

11. The method, according to claim 1, wherein ar islet-like tissue structure is produced after differentiation of said IPSCs.

12. A method for producing an endocrine hormone which comprises culturing pancreatic cells according to claim 1, and recovering said endocrine hormone from said pancreatic cell culture.

13. The method, according to claim 12, wherein said hormone is a human hormone.

14. The method, according to claim 12, wherein said hormone is a mouse hormone.

15. The method, according to claim 12, wherein differentiation is initiated at about 4 to 5 weeks of culture growth by re-feeding of said IPSC cell culture with said nutrient medium supplemented with normal serum.

16. The method, according to claim 12, wherein said endocrine hormone is selected from the group consisting of insulin, glucagon and somatostatin.

17. The method, according to claim 1, wherein the islet-like structure comprises cells selected from the group consisting of α

cells, β

cells and δ

cells.

18. A method for in vitro neogenesis of islet-like structures from pluripotent stem or progenitor cells which comprises:

a. establishing a stromal, or "nurse", cell monolayer of ductal pancreatic epithelial cells which permits the generation of IPSCs;

b. inducing stem/progenitor cell proliferation with culture conditions which promote cyclical regeneration of IPSCs and also prevent premature differentiation of the IPSC; and

c. expanding and differentiating the IPSCs to produce an islet-like structure comprising α

, β

, and δ

cells.

19. The method of in vitro neogenesis of islets according to claim 18 which comprises:

a dispersing and leaving undisturbed pancreatic cells in a minimal culture medium comprising little or no glucose, serum at a concentration below about 0.5%, essential amino acids for the cells of the species from which the pancreatic cells were obtained, and a rudimentary lipid source, until about 99% of the cells in said culture have died (phase I);

b. re-feeding the culture of step (a) with said minimal medium supplemented with about 1-10 mM glucose and about 0.5%-10% serum (but less than a toxic amount of said serum) and re-feeding about once a week until rapid proliferation occurs;

c. re-feeding the culture of step (b) with said minimal medium supplemented with said 0.5%-1 0% serum and about 10-25 mM glucose and, optimally, added growth or cellular factors (phase III);

d. allowing islet-like structures to bud into the medium; and

e. recovering said islet-like structures.